270 related articles for article (PubMed ID: 29627316)
1. KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
Ardeshir-Larijani F; Bhateja P; Lipka MB; Sharma N; Fu P; Dowlati A
Clin Lung Cancer; 2018 Jul; 19(4):e489-e501. PubMed ID: 29627316
[TBL] [Abstract][Full Text] [Related]
2. Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance).
Augert A; Zhang Q; Bates B; Cui M; Wang X; Wildey G; Dowlati A; MacPherson D
J Thorac Oncol; 2017 Apr; 12(4):704-713. PubMed ID: 28007623
[TBL] [Abstract][Full Text] [Related]
3. A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC).
Azad AK; Qiu X; Boyd K; Kuang Q; Emami M; Perera N; Palepu P; Patel D; Chen Z; Cheng D; Feld R; Leighl NB; Shepherd FA; Tsao MS; Xu W; Liu G; Cuffe S
Lung Cancer; 2014 Jun; 84(3):289-94. PubMed ID: 24679952
[TBL] [Abstract][Full Text] [Related]
4. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
5. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
6. Peripheral-type small cell lung cancer is associated with better survival and higher frequency of interstitial lung disease.
Kanaji N; Sakai K; Ueda Y; Miyawaki H; Ishii T; Watanabe N; Kita N; Kadota K; Kadowaki N; Bandoh S
Lung Cancer; 2017 Jun; 108():126-133. PubMed ID: 28625624
[TBL] [Abstract][Full Text] [Related]
7. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients.
Boros A; Lacroix L; Lacas B; Adam J; Pignon JP; Caramella C; Planchard D; de Montpreville V; Deutsch E; Levy A; Besse B; Le Pechoux C
Oncotarget; 2017 Apr; 8(15):25189-25199. PubMed ID: 28445990
[TBL] [Abstract][Full Text] [Related]
9. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
10. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
11. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
[TBL] [Abstract][Full Text] [Related]
14. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation.
Barquín M; Calvo V; García-García F; Nuñez B; Sánchez-Herrero E; Serna-Blasco R; Auglytė M; Carcereny E; Rodriguez-Abreu D; López Castro R; Guirado M; Camps C; Bosch-Barrera J; Massuti B; Ortega AL; Del Barco E; Gonzalez-Larriba JL; Aguiar D; García-Campelo R; Dómine M; Agraso S; Sala MA; Oramas J; Bernabé R; Blanco R; Parejo C; Cruz A; Menasalvas E; Royuela A; Romero A; Provencio M
Cancer Epidemiol; 2020 Aug; 67():101737. PubMed ID: 32450544
[TBL] [Abstract][Full Text] [Related]
15. KRAS Exon 3 and PTEN Exon 7 Mutations in Small-cell Lung Cancer.
Lei L; Jiang ZM; Li CH; Lu HY
Curr Med Sci; 2019 Jun; 39(3):379-384. PubMed ID: 31209806
[TBL] [Abstract][Full Text] [Related]
16. EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
Kumarakulasinghe NB; Syn N; Soon YY; Asmat A; Zheng H; Loy EY; Pang B; Soo RA
Oncotarget; 2016 Dec; 7(51):85542-85550. PubMed ID: 27907909
[TBL] [Abstract][Full Text] [Related]
17. Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
Simbolo M; Mafficini A; Sikora KO; Fassan M; Barbi S; Corbo V; Mastracci L; Rusev B; Grillo F; Vicentini C; Ferrara R; Pilotto S; Davini F; Pelosi G; Lawlor RT; Chilosi M; Tortora G; Bria E; Fontanini G; Volante M; Scarpa A
J Pathol; 2017 Mar; 241(4):488-500. PubMed ID: 27873319
[TBL] [Abstract][Full Text] [Related]
18. Thyroid transcription factor-1 expression in advanced non- small cell lung cancer: impact on survival outcome.
Elsamany SA; Al-Fayea TM; Alzahrani AS; Abozeed WN; Darwish W; Farooq MU; Almadani AS; Bukhari EA
Asian Pac J Cancer Prev; 2015; 16(7):2987-91. PubMed ID: 25854394
[TBL] [Abstract][Full Text] [Related]
19. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
[TBL] [Abstract][Full Text] [Related]
20. Prognostic implications of STK11 with different mutation status and its relationship with tumor-infiltrating immune cells in non-small cell lung cancer.
Zheng J; Deng Y; Huang B; Chen X
Front Immunol; 2024; 15():1387896. PubMed ID: 38736875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
